Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The intestinal glucose absorption transporter system is a complex network of proteins, primarily SGLT1 and GLUT2, responsible for the uptake of glucose from the intestinal lumen into enterocytes and its subsequent release into the bloodstream. SGLT1 mediates active transport of glucose with sodium, while GLUT2 facilitates passive diffusion. This system is critical for maintaining glucose homeostasis, and alterations can lead to diseases such as glucose-galactose malabsorption, diabetes, and obesity.
SGLT1 inhibitors block the reabsorption of glucose in the kidney and intestine, promoting its excretion in the urine and reducing blood glucose levels. This reduces glucose absorption from intestine. Some agents also affect incretin hormone secretion.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal Glucose Absorption Transporter System.